Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Bernabeu

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
European Journal of Endocrinology|October 6, 2012
Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analoguesJosep Oriola, Tomás Lucas, Irene Halperin, et al.
Clinical Therapeutics|February 2, 2020
GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical PracticeOlaia Díaz-Trastoy, Rocío Villar-Taibo, Mildred Sifontes-Dubón, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|July 25, 2016
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB studyManuel Puig-Domingo, Alfonso Soto, Eva Venegas, et al.
Pituitary|April 7, 2012
Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)Gemma Sesmilo, Sonia Gaztambide, Eva Venegas, et al.
Clinical Endocrinology|March 12, 2014
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyGemma Sesmilo, Eugenia Resmini, Ignacio Bernabeu, et al.
Biomedicines|February 25, 2022
Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic ResponseJoan Gil, Montserrat Marques-Pamies, Elena Valassi, et al.
Ebiomedicine|April 13, 2019
Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegalyMiguel Chenlo, Iria A Rodriguez-Gomez, Ramon Serramito, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|March 20, 2012
[Neuroendocrinology in 2011]Manel Puig Domingo, Justo Castaño, Cristina Alvarez-Escolá, et al.
Clinical Endocrinology|July 8, 2023
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegalySabina Ruiz, Joan Gil, Betina Biagetti, et al.
Endocrinology|August 20, 2014
Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNFEsther Diaz-Rodriguez, Angela R Garcia-Rendueles, Alejandro Ibáñez-Costa, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
European Journal of Endocrinology|October 6, 2012
Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analoguesJosep Oriola, Tomás Lucas, Irene Halperin, et al.
Clinical Therapeutics|February 2, 2020
GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical PracticeOlaia Díaz-Trastoy, Rocío Villar-Taibo, Mildred Sifontes-Dubón, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|July 25, 2016
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB studyManuel Puig-Domingo, Alfonso Soto, Eva Venegas, et al.
Pituitary|April 7, 2012
Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)Gemma Sesmilo, Sonia Gaztambide, Eva Venegas, et al.
Clinical Endocrinology|March 12, 2014
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyGemma Sesmilo, Eugenia Resmini, Ignacio Bernabeu, et al.
Biomedicines|February 25, 2022
Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic ResponseJoan Gil, Montserrat Marques-Pamies, Elena Valassi, et al.
Ebiomedicine|April 13, 2019
Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegalyMiguel Chenlo, Iria A Rodriguez-Gomez, Ramon Serramito, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|March 20, 2012
[Neuroendocrinology in 2011]Manel Puig Domingo, Justo Castaño, Cristina Alvarez-Escolá, et al.
Clinical Endocrinology|July 8, 2023
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegalySabina Ruiz, Joan Gil, Betina Biagetti, et al.
Endocrinology|August 20, 2014
Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNFEsther Diaz-Rodriguez, Angela R Garcia-Rendueles, Alejandro Ibáñez-Costa, et al.
Pageof 5